Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.J Clin Oncol. 2010; 28: 4199-4206
- Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma.N Engl J Med. 2010; 363: 640-652
- Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.J Clin Oncol. 2017; 35: 1999-2007
- Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F Intergroup Randomized Trial.Int J Radiat Oncol Biol Phys. 2018; 100: 1133-1145
- Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.N Engl J Med. 2015; 372: 1598-1607
- Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial.J Clin Oncol. 2017; 35: 1786-1794
- PET-guided treatment of early-stage favorable Hodgkin lymphoma: final results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group.Blood. 2018; 132: 925
- Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma.Int J Radiat Oncol Biol Phys. 2013; 85: 1057-1065
- Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG).Int J Radiat Oncol Biol Phys. 2014; 89: 854-862
- Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.J Clin Oncol. 2011; 29: 4234-4242
- BEACOPP-escalated followed by radiotherapy of initial bulk or residual disease in advanced stage Hodgkin lymphoma: long-term follow up of the HD9 and HD12 trials of the German Hodgkin Study Group.Blood. 2016; 128: 923
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.Lancet. 2012; 379: 1791-1799
- Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma.N Engl J Med. 2016; 374: 2419-2429
- Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial.J Clin Oncol. 2018; 36: 454-462
- Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma--a matched pair analysis from the German Hodgkin Study Group (GHSG).Br J Haematol. 2014; 167: 238-242
- Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.Int J Radiat Oncol Biol Phys. 2015; 92: 67-75
- Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.Haematologica. 2015; 100: 1579-1586
- Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up.J Clin Oncol. 2010; 28: 136-141
- Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.J Clin Oncol. 2004; 22: 3032-3038
- Chemotherapy alone with the ACVBP regimen is superior to three cycles of CHOP plus radiotherapy for treatment of low risk localized aggressive lymphoma: the LNH93-1 GELA study.Blood. 2003; 100: 93a
- CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.J Clin Oncol. 2007; 25: 787-792
- Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma.N Engl J Med. 1998; 339: 21-26
- Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736.J Clin Oncol. 2016; 34: 2997-3004
- Diffuse large B-cell lymphoma in very elderly patients over 80 years old: incorporating consolidative radiation therapy into management decisions.Adv Radiat Oncol. 2017; 2: 370-380
- Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.Leuk Lymphoma. 2015; 56: 716-724
- Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.J Clin Oncol. 2013; 31: 4115-4122
- Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.J Clin Oncol. 2014; 32: 1112-1118
- Radiotherapy to bulky and extralymphatic disease in combination with 6×R-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: results of the 2×2 randomized UNFOLDER trial of the DSHNHL/GLA.J Clin Oncol. 2018; 36 ([abstract: 7574])
- R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma.Blood. 2018; 131: 174-181
- Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.Radiother Oncol. 2011; 100: 86-92
- Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy.Cancer. 2012; 118: 4156-4165
- Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma.Radiother Oncol. 2013; 109: 133-139
- Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group.Int J Radiat Oncol Biol Phys. 2015; 92: 11-31
- Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.Int J Radiat Oncol Biol Phys. 2014; 89: 49-58
- Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG.Blood. 2019; 133: 237-245
- Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG.Int J Radiat Oncol Biol Phys. 2019; 104: 522-529
- Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy.Cancer. 2010; 116: 3797-3806
- Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: results of a multicenter study.Int J Radiat Oncol Biol Phys. 2016; 94: 783-791
- Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03.J Clin Oncol. 2018; 36: 2918-2925
- Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas.Leuk Lymphoma. 2009; 50: 1765-1772
- Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas.Hematol Oncol. 1994; 12: 1-8
- A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment.Int J Radiat Oncol Biol Phys. 2001; 51: 148-155
- High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.J Clin Oncol. 2003; 21: 2474-2480
- Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma.Radiother Oncol. 1997; 42: 49-51
- Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.Ann Oncol. 2008; 19: 2043-2047
- Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.Int J Radiat Oncol Biol Phys. 2013; 86: 121-127
- 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.Lancet Oncol. 2014; 15: 457-463
- Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone.J Clin Oncol. 1998; 16: 1916-1921
- Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue (MALT) lymphoma.Int J Radiat Oncol Biol Phys. 2019; 104: 447-455
- Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.Int J Radiat Oncol Biol Phys. 2012; 84: e329-e335
- Survival and neurocognitive outcomes after cranial or craniospinal irradiation plus total-body irradiation before stem cell transplantation in pediatric leukemia patients with central nervous system involvement.Int J Radiat Oncol Biol Phys. 2014; 89: 67-74
- Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group.Int J Radiat Oncol Biol Phys. 2018; 102: 53-58
- How I treat extramedullary acute myeloid leukemia.Blood. 2011; 118: 3785-3793
- Use of radiation in extramedullary leukemia/chloroma: guidelines from the International Lymphoma Radiation Oncology Group.Int J Radiat Oncol Biol Phys. 2018; 102: 314-319
- Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the International Lymphoma Radiation Oncology Group.Int J Radiat Oncol Biol Phys. 2018; 101: 794-808
- Extramedullary plasmacytomas of the head and neck.Otolaryngol Head Neck Surg. 1993; 109: 877-885
- Clinical course of solitary extramedullary plasmacytoma.Radiother Oncol. 1999; 52: 245-249
- Definitive radiotherapy for extramedullary plasmacytomas of the head and neck.Br J Radiol. 2003; 76: 738-741
- Solitary plasmacytoma.Am J Clin Oncol. 2009; 32: 612-617
- Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.Int J Radiat Oncol Biol Phys. 2006; 64: 210-217
- Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.Int J Radiat Oncol Biol Phys. 2017; 99: 825-842
- Effect of akimbo versus raised arm positioning on breast and cardiopulmonary dosimetry in pediatric Hodgkin lymphoma.Front Oncol. 2016; 6: 176
- Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?.Int J Radiat Oncol Biol Phys. 2015; 92: 169-174
- Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma.Int J Radiat Oncol Biol Phys. 2012; 82: 1522-1527
- Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and/or deep inspiration breath hold.Radiother Oncol. 2017; 125: 41-47
- Pencil beam algorithms are unsuitable for proton dose calculations in lung.Int J Radiat Oncol Biol Phys. 2017; 99: 750-756
- Relative biological effectiveness (RBE) values for proton beam therapy.Int J Radiat Oncol Biol Phys. 2002; 53: 407-421
- Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations.Radiat Oncol. 2012; 7: 186
- Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma.Radiat Oncol. 2014; 9: 94
- Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma.Radiother Oncol. 2018; 129: 449-455
- Comparison of radiation techniques in lower mediastinal lymphoma.Int J Radiat Oncol Biol Phys. 2018; 102: S190-S191
- Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines.Blood. 2018; 132: 1635
- Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: effectiveness and toxicity after photon or proton treatment.Pract Radiat Oncol. 2017; 7: e401-e408
- Int J Radiat Oncol Biol Phys. 2011; 79: 10-18
Article info
Publication history
Published online: October 28, 2019
Footnotes
Disclosure: The authors have nothing to disclose.
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
